×
The Training Management System (TMS) is undergoing scheduled maintenance on Tuesday 3 October 2023 from 8:00pm to 9:00pm AEDT. During this time, the application will be unavailable. We apologise for any inconvenience caused.

Prescribing drugs of dependence in general practice

Part B - Benzodiazepines - Chapter 4

Duration of benzodiazepine therapy

Part B - Benzodiazepines
    5. Duration of benzodiazepine therapy
Download PDF

Last revised: 06 Nov 2019

Overview

Optimal duration of therapy

Guidelines and formularies typically give durations of 1–4 weeks for benzodiazepine therapy, depending on the indication. Short-term therapy is generally advised to reduce the risk of dependence and withdrawal, as well as other potential harm such as cognitive impairment. Short-term therapy does not reduce the risk of accidents or falls.

Dependence is recognised as a risk in some patients who receive treatment for longer than 1 month, and health professionals should be conscious of this when considering the relative benefits and risks of treatment.25

The 1–4 week time frame is not based on risk–benefit data; rather that no substantive placebo-controlled trials of hypnotics have been carried out for longer than a few weeks. The available evidence does not suggest there is an unfavourable risk–benefit transition at 3–4 weeks for any agent.101

Patients who are prescribed benzodiazepines for problems relating to anxiety or sleep usually do not escalate their doses even over a lengthy period of use.185 A 2013 study found most patients use benzodiazepines according to guidelines, and only 0.9% ended up as excessive users after 3 years.76 Excessive use occurred mostly in individuals with alcohol and drug histories.

Lacking the means to determine the optimal duration of therapy, a rational approach is to allow the duration of treatment to be determined by a series of risk–benefit decisions and shared decision making, with periodic trials of tapering and discontinuing medication to determine whether continued therapy is indicated.101,186 This approach provides an ‘exit strategy’ and thereby addresses concerns that once started, hypnotic therapy could be unending.101

Clinical discipline and accountable prescribing are essential when considering long-term benzodiazepine therapy.

While the optimum duration of therapy is not clear from the evidence, there are very few specific indications for the chronic use of benzodiazepines. The decision to prescribe benzodiazepines longer term should be uncommon and made with caution. Assume that all patients are at risk of dependence.

Benzodiazepines may be used for longer than 4 weeks in selected cases. Patients who are terminally ill or severely handicapped, where it is clear that the benefits outweigh the risks and side effects, or where a detailed individual assessment has been made with a patient and their family or carers.

Benzodiazepines may also be indicated in certain neurological disorders (eg stiff person syndrome) and in neuromuscular conditions where spasticity is problematic. Increasingly, benzodiazepines are being used off-label for indications (eg drug-induced movement disorders, restless legs syndrome, acute psychotic agitation, terminal agitation, nausea and vomiting, intractable pruritus and intractable hiccup).187

Recommendations supporting the long-term use of benzodiazepines for any mental illness or chronic sleep disorder come from evidence limited to shorter time frames. Hence, longer duration of prescribing should occur in conjunction with heightened clinical surveillance.

The principles of universal precautions apply. Ensure a clear diagnosis is formed, comprehensive assessment is undertaken, clear treatment plan is discussed with the patient and information is provided to the patient to enable informed consent. The negotiated treatment plan will have clearly defined time limit and goals of treatment.

Benzodiazepines are generally regarded by clinical practice guidelines as a short-term therapeutic option. Long-term use, beyond 4 weeks, is not generally advocated by clinical practice guidelines, hence long-term therapy should be should be uncommon and made with caution.

Prescribing benzodiazepines, like other aspects of clinical practice, should be based on thoughtful consideration of the likely risks and benefits, and the risks and benefits of alternative interventions. This decision should be made in conjunction with the patient and their carers, where appropriate.100 Benzodiazepines may be prescribed longer term where:

  • patients do not respond to, or cannot tolerate, numerous first-line therapies130,188
  • use is intermittent
  • specialists make a recommendation and are able to provide a rationale of therapy.

For some patients, benzodiazepine alternatives fail, have limited benefit, are unavailable or clinically inappropriate. If there is no history of drug dependence, positive indicative ‘lifestyle’ factors are present and a clinical decision for benzodiazepine treatment can be justified, then long-term therapy should not necessarily be regarded as a deviation from good clinical practice.25 Supervised benzodiazepine treatment may remain an acceptable long-term therapeutic option for some patients.

Many patients are able to safely take short courses of benzodiazepines, or to use them intermittently longer term, on a ‘as required’ basis and to stop them when no longer needed.25,113

In a situation where the clinical decision is that the ongoing use of a benzodiazepine is the most appropriate management, this requires ongoing monitoring of health outcomes and continuing vigilance for potential hazards throughout treatment.25

The responsible specialist or GP should clearly outline a prescribing plan that should be documented in the patients’ notes or management plan.

The prescribing plan may include instructions that:

  • regular prescription reviews take place
  • no repeat prescriptions will be made without face-to-face contact
  • all prescriptions will be made by one doctor within a single practice
  • one pharmacy will dispense all medication.

Benzodiazepine prescriptions should be at the lowest effective dose and given intermittently, with regular reviews of the treatment plans and regular attempts at withdrawal.

At the time of benzodiazepine prescription renewal or medication review, GPs should continue to discuss the risks of long-term benzodiazepines and the benefits of discontinuation (eg cognition, mood, sleep and energy level) and advise the patient to reduce or discontinue the benzodiazepines if there are issues. GPs should document this communication.

Patients should be monitored closely for problematic use or any therapeutic dose dependence behaviour. Any escalation of dose or inappropriate use would lead to a complete review of prescribing and attempted withdrawal of benzodiazepine, along with a review of alternative therapy.

Refer to Resource E.2 in the PDF version for an example of a prescription plan/agreement.

All GPs should develop strategies to manage inappropriate requests for benzodiazepines.

  1. Mehdi T. Benzodiazepines revisited. BJMP 2012;5(1):a501.
  2. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005;18(3):249–55.
  3. Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2013;28(1):7–20
  4. Committee on Safety of Medicines. Current problems – Benzodiazepines, dependence and withdrawal symptoms. London: Committee on Safety of Medicines, 1988. [Accessed 12 June 2015]
  5. Islam MM, Conigrave KM, Day CA, Nguyen Y, Haber PS. Twenty-year trends in benzodiazepine dispensing in the Australian population. Intern Med J 2014;44(1):57–64. [Accessed 12 June 2015]
  6. Nicholas R, Lee N, Roche A. Pharmaceutical drug misuse in Australia: Complex issues, balanced responses. Adelaide: National Centre for Education and Training on Addiction (NCETA); 2011. [Accessed 12 June 2015]
  7. Drugs and Crime Prevention Committee (DCPC). Inquiry into the misuse/abuse of benzodiazepines and other forms of pharmaceutical drugs in Victoria – Final report. Melbourne: DCPC; 2007. [Accessed 12 June 2015]
  8. Sirdifield C, Anthierens S, Creupelandt H, et al. General practitioners’ experiences and perceptions of benzodiazepine prescribing: Systematic review and meta-synthesis. BMC Fam Pract 2013;14:191. [Accessed 12 June 2015]
  9. Balon R. Benzodiazepines revisited. Psychother Psychosom. 2013;82(6):353–54. [Accessed 12 June 2015]
  10. Haw C, Stubbs J. Benzodiazepines – A necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. J Psychopharmacol 2007;21(6):645–9. [Accessed 12 June 2015]
  11. Medicare Australia Statistics. Pharmaceutical Benefits Schedule Item Reports [internet]. [Accessed 4 April 2014].
  12. Coroners Court of Victoria. Coroners Prevention Unit – Pharmaceutical drugs in fatal overdose: A coroner’s perspective. Melbourne: Coroners Court of Victoria; 2015. [internet]. [Accessed 4 April 2014].
  13. Hollingworth SA, Siskind DJ, Nissen LM, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia 2002–2007. Aust N Z J Psychiatry 2010;44(4):372–7 [internet]. [Accessed 4 April 2014].
  14. Britt HC, Miller GC, Henderson J, et al. A decade of Australian general practice activity 2003–04 to 2012–13. Sydney: Sydney University Press; 2013 [internet]. [Accessed 4 April 2014].
  15. Rintoul AC, Dobbin MD, Nielsen S, Degenhardt L, Drummer OH. Recent increase in detection of alprazolam in Victorian heroin-related deaths. Med J Aust 2013;198(4):206–09. [internet]. [Accessed 4 April 2014].
  16. Australian Institute of Health and Welfare. 2010 National Drug Strategy Household Survey report. Cat. no. PHE 145. Canberra: AIHW; 2011. [internet]. [Accessed 4 April 2014].
  17. McGregor C, Gately N, Flemming J. Prescription drug use among detainees: Prevalence, sources and links to crime. Trends and issues in crime and criminal justice no.423. Canberra: Australian Institute of Criminology; 2011. [internet]. [Accessed 4 April 2014].
  18. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: A systematic review. BMC Fam Pract 2012;13:40. [internet]. [Accessed 4 April 2014].
  19. Nielsen S, Bruno R, Degenhardt L, et al. The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Med J Aust 2013;199(10):696–99 [internet]. [Accessed 4 April 2014].
  20. Alcohol and other Drugs Council of Australia (ADCA). Misuse of prescription drugs. Canberra: ADCA; 2003. [internet]. [Accessed 4 April 2014].
  21. Mental Health and Drug and Alcohol Office (MHDAO). NSW Opioid Treatment Program: Clinical guidelines for methadone and buprenorphine treatment. Sydney: MHDAO; 2006 [internet]. [Accessed 4 April 2014].
  22. Pilgrim JL, McDonough M, Drummer OH. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. Forensic Sci Int 2013;226(1–3):216–22. [internet]. [Accessed 4 April 2014].
  23. Ross J, Darke S. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction 2000;95(12):1785–93 [internet]. [Accessed 4 April 2014].
  24. Kirwan A, Dietze P, Lloyd B. Victorian drug trends 2011: findings from the Illicit Drug Reporting System (IDRS). Sydney: National Drug and Alcohol Reseach Centre, University of New South Wales; 2012. [internet]. [Accessed 4 April 2014].
  25. Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol 2013;27(11):967–71. [internet]. [Accessed 4 April 2014].
  26. Quaglio G, Lugoboni F, Fornasiero A, et al. Dependence on zolpidem: two case reports of detoxification with flumazenil infusion. Int Clin Psychopharmacol 2005;20(5):285–87 [internet]. [Accessed 4 April 2014].
  27. Sethi PK, Khandelwal DC. Zolpidem at supratherapeutic doses can cause drug abuse, dependence and withdrawal seizure. J Assoc Physicians India 2005;53:139–40. [internet]. [Accessed 4 April 2014].
  28. Harter C, Piffl-Boniolo E, Rave-Schwank M. Development of drug withdrawal delirium after dependence on zolpidem and zoplicone. Psychiatr Prax 1999;26(6):309. [internet]. [Accessed 4 April 2014].
  29. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345:e8343 [internet]. [Accessed 4 April 2014].
  30. Mental Health and Drug and Alcohol Office (MHDAO). NSW Drug and Alcohol Withdrawal Clinical Practice Guidelines. Sydney: MHDAO; 2008. [internet]. [Accessed 4 April 2014].
  31. World Health Organization. Lexicon of alcohol and drug terms published by the World Health Organization. Geneva: WHO; 2014 [Accessed 14 January 2014]. [internet]. [Accessed 4 April 2014].
  32. Vinkers CH, Olivier B. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators? Adv Pharmacol Sci 2012;2012:416864. [internet]. [Accessed 4 April 2014].
  33. Longo LP, Johnson B. Addiction: Part I. Benzodiazepines – Side effects, abuse risk and alternatives. Am Fam Physician 2000;61(7):2121–28 [internet]. [Accessed 4 April 2014].
  34. Argyropoulos SV, Nutt DJ. The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol 1999;9 Suppl 6:S407–12 [internet]. [Accessed 4 April 2014].
  35. Therapeutic Guidelines. eTG complete [internet.] Melbourne: Therapeutic Guidelines Limited; 2013 [Accessed 26 Decemeber 2013] [internet]. [Accessed 4 April 2014].
  36. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: A meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999;14(5):287–303. [internet]. [Accessed 4 April 2014].
  37. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 1987;82(6):665–71. [internet]. [Accessed 4 April 2014].
  38. Ford C, Law F. Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice. London: SMMGP; 2014. [internet]. [Accessed 4 April 2014].
  39. Smith DE, Wesson DR. Benzodiazepine dependency syndromes. J Psychoactive Drugs 1983;15(1–2):85–95 [internet]. [Accessed 4 April 2014].
  40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Arlington VA: American Psychiatric Publishing; 2013. [internet]. [Accessed 4 April 2014].
  41. Willems IA, Gorgels WJ, Oude Voshaar RC, Mulder J, Lucassen PL. Tolerance to benzodiazepines among long-term users in primary care. Fam Pract 2013;30(4):404–10. [internet]. [Accessed 4 April 2014].
  42. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 2013;13(2):214–23. [internet]. [Accessed 4 April 2014].
  43. Roche. Valium (diazepam) Product Information. Date of first TGA inclusion 1994. Date of most recent amendment 2012. Sydney: Roche Products Pty Ltd; 2012. [internet]. [Accessed 4 April 2014].
  44. Alphapharm. Kalma (alprazolam) Product Information. Date of first TGA inclusion 1998. Most recent amendment 2014. Sydney: Alphapharm Pty Ltd; 2014. [internet]. [Accessed 4 April 2014].
  45. Alphapharm. Temaze (temazepam) Product Information. Date of first TGA inclusion 1998. Date of most recent amendment 2014. Sydney: Alphapharm Pty Ltd; 2014. [internet]. [Accessed 4 April 2014].
  46. Aspen. Ativan (lorazepam) Product Information. Date of first TGA inclusion 1993. Date of most recent amendment 2013. Sydney: Aspen Pharma Pty Ltd; 2013. [internet]. [Accessed 4 April 2014].
  47. Tiplady B, Bowness E, Stien L, Drummond G. Selective effects of clonidine and temazepam on attention and memory. J Psychopharmaco 2005;19(3):259–65. [internet]. [Accessed 4 April 2014].
  48. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002;8(1):45–58. [internet]. [Accessed 4 April 2014].
  49. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs 2004;18(1):37–48. [internet]. [Accessed 4 April 2014].
  50. Billioti de Gage S, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: Prospective population based study. BMJ 2012;345:e6231. [internet]. [Accessed 4 April 2014].
  51. Wu CS, Wang SC, Chang IS, Lin KM. The association between dementia and long-term use of benzodiazepine in the elderly: Nested casecontrol study using claims data. Am J Geriatr Psychiatry 2009;17(7):614–20. [internet]. [Accessed 4 April 2014].
  52. Gallacher J, Elwood P, Pickering J, et al. Benzodiazepine use and risk of dementia: Evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 2012;66(10):869–73. [internet]. [Accessed 4 April 2014].
  53. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer’s disease: Successive emergence of the clinical symptoms. Ann Neurol 2008;64(5):492–98. [internet]. [Accessed 4 April 2014].
  54. Mura T, Proust-Lima C, Akbaraly T, et al. Chronic use of benzodiazepines and latent cognitive decline in the elderly: Results from the Threecity study. Eur Neuropsychopharmacol 2013;23(3):212–23. [internet]. [Accessed 4 April 2014].
  55. Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: A systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011;34(2):125–56. [internet]. [Accessed 4 April 2014].
  56. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004;65 Suppl 5:7–12. [internet]. [Accessed 4 April 2014].
  57. Ashton H. Benzodiazepines: How they work and how to withdraw. Newcastle: The Ashton Manual; 2002. [internet]. [Accessed 4 April 2014].
  58. Nielsen M, Hansen EH, Gotzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 2012;107(5):900–08. [internet]. [Accessed 4 April 2014].
  59. Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 1991;8(1–2):19–28. [internet]. [Accessed 4 April 2014].
  60. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl 1998;393:95–101. [internet]. [Accessed 4 April 2014].
  61. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev 2014;3:Cd009178. [internet]. [Accessed 4 April 2014].
  62. Olsen Y. Clinical Guidelines for the use of benzodiazepines among patients receiving medication assissted treatment for opioid dependence. Baltimore: Baltimore Sustance Abuse Systems; 2013. [internet]. [Accessed 4 April 2014].
  63. van Marwijk H, Allick G, Wegman F, Bax A, Riphagen, II. Alprazolam for depression. Cochrane Database Syst Rev. 2012;7:CD007139. [internet]. [Accessed 4 April 2014].
  64. Guideline Working Group for the Treatment of Patients with Anxiety Disorders in Primary Care. Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care. UETS no 2006/10 ed. Madrid: National Plan for the NHS of the MSC. Health Technology Assessment Unit; 2008. [internet]. [Accessed 4 April 2014].
  65. Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315(14):854–59. [internet]. [Accessed 4 April 2014].
  66. Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf 2014;13(7):919–34. [internet]. [Accessed 4 April 2014].
  67. Kenny P, Swan A, Berends L, et al. Alcohol and other drug withdrawal: Practice guidelines 2009. Melbourne: Turning Point Alcohol and Drug Centre; 2009. [internet]. [Accessed 4 April 2014].
  68. Psychotropic Drugs Committee. Practice Guideline 5: Guidelines for use of benzodiazepines in psychiatric practice: Royal Australian and New Zealand College of Psychiatrists. Melbourne 2008 (update, first issued 1991). [internet]. [Accessed 4 April 2014].
  69. Reconnexion. Beyond benzodiazepines: Helping people recover from benzodiazepine dependence and withdrawal – For health practitioners. Redman T, Cannard G, editors. Melbourne: Reconnexion Inc; 2010. [internet]. [Accessed 4 April 2014].
  70. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs1998;10(6):425–40. [internet]. [Accessed 4 April 2014].
  71. Ashton H. Benzodiazepine dependency. In: Baum A, Newman S, Weinman J, West R, McManus C, editors. Cambridge Handbook of Psychology and Medicine. Cambridge: Cambridge University Press; 1997. [internet]. [Accessed 4 April 2014].
  72. Balter MB, Ban TA, Uhlenhuth EH. International study of expert judgment on therapeutic use of benzodiazepines and other pyschotherapeutic medications: I. Current concerns. Hum Psychopharmacol Clin Exp 1993;8:253–61. [internet]. [Accessed 4 April 2014].
  73. Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother 2014:1–12. [internet]. [Accessed 4 April 2014].
  74. American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine dependence, toxicity, and abuse. Washington, DC: AMA; 1990. [internet]. [Accessed 4 April 2014].
  75. Sheehan D, Raj A. Benzodiazepines. In: Shatzberg A, Nemeroff C, editors. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th edn. Arlington, VA: American Psychiatric Publishing; 2009. [internet]. [Accessed 4 April 2014].
  76. Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open 2013;3(10):e003296. [internet]. [Accessed 4 April 2014].
  77. Longo LP, Parran T, Jr., Johnson B, Kinsey W. Addiction: Part II. Identification and management of the drug-seeking patient. Am Fam Physician 2000;61(8):2401–08. [internet]. [Accessed 4 April 2014].
  78. Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health 1990;80(12):1467–70. [internet]. [Accessed 4 April 2014].
  79. Lloyd B. Trends in alcohol and drug related ambulance attendences in Melbourne 2010–11. Melbourne: Turning Point Alcohol and Drug Centre; 2012. [internet]. [Accessed 4 April 2014].
  80. Lloyd B. Ambo Project: Alcohol and drug related ambulance attendance in Victoria 2011–12. Melbourne: Turning Point Alcohol and Drug Centre and Ambulance Victoria; 2013. [internet]. [Accessed 4 April 2014].
  81. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003;348(1):42–49. [internet]. [Accessed 4 April 2014].
  82. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319(26):1701–07. [internet]. [Accessed 4 April 2014].
  83. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009;169(21):1952–60. [internet]. [Accessed 4 April 2014].
  84. Kripke DF Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: A matched cohort study. BMJ Open 2012;2(1):e000850. [internet]. [Accessed 4 April 2014].
  85. Jaussent I, Ancelin ML, Berr C, et al. Hypnotics and mortality in an elderly general population: A 12-year prospective study. BMC Med 2013;11:212. [internet]. [Accessed 4 April 2014].
  86. National Institute on Drug Abuse. Prescription Drugs: Abuse and Addiction: NIDA; 2001, revised 2011. [internet]. [Accessed 4 April 2014].
  87. Heit HA, Lipman AG. Pain: Substance Abuse Issue in the Treatment of Pain. In: Moore RJ, editor. Biobehavioral Approaches to Pain. New York: Springer Science+Business Media, LLC; 2009. [internet]. [Accessed 4 April 2014].
  88. Johnson C, Baxter B, Brough R, Buchanan J. Benzodiazepine prescribing: Lessons from interprofessional dialogue. Aust Fam Physician 2007;36(4):245–46. [internet]. [Accessed 4 April 2014].
  89. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19(6):567–96. [internet]. [Accessed 4 April 2014].
  90. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: A systematic review and meta-analysis. Br J Gen Pract 2011;61(590):e573–78. [internet]. [Accessed 4 April 2014].
  91. de Gier NA, Gorgels WJ, Lucassen PL, et al. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract 2011;28(3):253–59. [internet]. [Accessed 4 April 2014].
  92. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER Cluster Randomized Trial. JAMA Intern Med 2014;174(6):890–98. [internet]. [Accessed 4 April 2014].
  93. Spinks A, Bulbeck K, Del Mar C, Glasziou P, Nikles J, Group AcftPBW. Using benzodiazeines: the best evidence. Brisbane: Centre for General Practice, The University of Queensland; 2000. [internet]. [Accessed 4 April 2014].
  94. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 2012;16(2):77–84. [internet]. [Accessed 4 April 2014].
  95. Rogers A, Pilgrim D, Brennan S, et al. Prescribing benzodiazepines in general practice: a new view of an old problem. Health (London) 2007;11(2):181–98. [internet]. [Accessed 4 April 2014].
  96. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015;84(2):72–81. [internet]. [Accessed 4 April 2014].
  97. Nielsen M, Hansen EH, Gotzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? Int J Risk Saf Med 2013;25(3):155–68. [internet]. [Accessed 4 April 2014].
  98. Evans EA, Sullivan MA. Abuse and misuse of antidepressants. Subst Abuse Rehabil 2014;5:107–20. [internet]. [Accessed 4 April 2014].
  99. Klein-Schwartz W, Schwartz EK, Anderson BD. Evaluation of quetiapine abuse and misuse reported to poison centers. J Addict Med 2014;8(3):195–98. [internet]. [Accessed 4 April 2014].
  100. Martin P, Tamblyn R, Ahmed S, Tannenbaum C. A drug education tool developed for older adults changes knowledge, beliefs and risk perceptions about inappropriate benzodiazepine prescriptions in the elderly. Patient Educ Couns 2013;92(1):81–7. [internet]. [Accessed 4 April 2014].
  101. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24(11):1577–601. [internet]. [Accessed 4 April 2014].
  102. Ministry of Health Singapore. Prescribing of Benzodiazepines: MOH Clinical Practice Guidelines 2/2008. Singapore: MOH; 2008. [internet]. [Accessed 4 April 2014].
  103. Guideline Working Group for the Treatment of Patients with Insomnia in Primary Care. Clinical Practice Guidelines for the Management of Patients with Insomnia in Primary Care. UETS No 2007/5–1. Madrid: Ministry of Health and Social Policy. Health Technology Assessment Unit; 2009. [internet]. [Accessed 4 April 2014].
  104. Britt HC, Miller GC, Henderson J, et al. General practice activity in Australia 2009–10. Canberra: Australian Institute of Health of Welfare; 2010. [internet]. [Accessed 4 April 2014].
  105. Pagel JF, Parnes BL. Medications for the treatment of sleep disorders: An overview. Prim Care Companion J Clin Psychiatry 2001;3(3):118–25. [internet]. [Accessed 4 April 2014].
  106. Wilson S, Nutt DJ. Recommended diagnosis and management of insomnia. Prescriber 2014. [internet]. [Accessed 4 April 2014].
  107. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13–15, 2005. Sleep 2005;28(9):1049–57. [internet]. [Accessed 4 April 2014].
  108. Bonnet M, Arand D. Treatment of insomnia [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  109. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998;158(10):1099–107. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  110. Krystal AD. Psychiatric comorbidity: the case for treating insomnia. Sleep Med Clin 2006;1:359. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  111. Cunnington D, Junge MF, Fernando AT. Insomnia: prevalence, consequences and effective treatment. Med J Aust 2013;199(8):S36–40. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  112. Cunnington D. Non-benzodiazepine hypnotics: do they work for insomnia? BMJ 2013;346:e8699. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  113. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4(5):487–504. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  114. Arroll B, Fernando A 3rd, Falloon K, Warman G, Goodyear-Smith F. Development, validation (diagnostic accuracy) and audit of the Auckland Sleep Questionnaire: a new tool for diagnosing causes of sleep disorders in primary care. J Prim Health Care 2011;3(2):107–13. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  115. Kierlin L. Sleeping without a pill: non pharmacological treatments for insomnia. J Pscychiatr Pract 2008;14(6):403–07. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  116. Hasora P, Kessmann J. Nonpharmacological management of chronic insomnia. Am Fam Physician 2009;79(2):125–30. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  117. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003(1):CD003161. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  118. Buysse DJ, Germain A, Moul DE, et al. Efficacy of brief behavioral treatment for chronic Insomnia in older adults. Arch Intern Med 2011;171(10):887–95. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  119. Fernando A 3rd, Arroll B, Falloon K. A double-blind randomised controlled study of a brief intervention of bedtime restriction for adult patients with primary insomnia. J Prim Health Care 2013;5(1):5–10. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  120. Troxel WM, Germain A, Buysse DJ. Clinical management of insomnia with brief behavioral treatment (BBTI). Behav Sleep Med 2012;10(4):266–79. [internet].Waltham, MA: UpToDate; 2014 [updated 17 April 2015]. [Accessed 4 April 2014].
  121. The Royal Australian College of General Practitioners. Brief behavioural therapy: insomnia in adults. Melbourne: RACGP; 2014. [Accessed 4 October 2014].
  122. Montgomery P, Dennis J. Physical exercise for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2002(4):CD003404. [Accessed 4 October 2014].
  123. Riemann D, Perlis ML. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev 2009;13(3):205–14. [Accessed 4 October 2014].
  124. Therapeutic Goods Administration (TGA). Zolpidem (Stilnox®) and next day impairment. Canberra: Australian Government Department of Health; 2014 [updated 1 August 2014]. [Accessed 2 September 2014].
  125. National Precribing Service. Melatonin prolonged-release tablets (Circadin®) for insmonia. Sydney: NPS; 2011. [updated 1 August 2014]. [Accessed 2 September 2014].
  126. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16(4):372–80. [updated 1 August 2014]. [Accessed 2 September 2014].
  127. Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol 2013;69(4):1–10. [updated 1 August 2014]. [Accessed 2 September 2014].
  128. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(5):403–39. [updated 1 August 2014]. [Accessed 2 September 2014].
  129. Mental Health: Australian Bureau of Statistics; 2010 [updated 13 November 2013]. [Accessed 27 December 2013].
  130. Canadian Agency for Drugs and Technologies in Health. Short- and Long-Term Use of Benzodiazepines in Patients with Generalized Anxiety Disorder: A Review of Guidelines. Ottawa: CADTH; 2014. [updated 13 November 2013]. [Accessed 27 December 2013].
  131. National Collaborating Centre for Mental Health. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. National Institute for Health and Care Excellence clinical guideline 113. London: NICE; 2011. [updated 13 November 2013]. [Accessed 27 December 2013].
  132. Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorders. P T 2013;38(1):30–57. [updated 13 November 2013]. [Accessed 27 December 2013].
  133. The Royal Australian College of General Practitioners. Depression and anxiety: Internet based or computerised CBT (iCBT or CCBT). Melbourne: RACGP; 2014. [Accessed 4 October 2014].
  134. The Royal Australian college of General Practitioners. Bibliotherapy: Depression. Melbourne: RACGP; 2014. [Accessed 4 October 2014].
  135. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 2007;8(3):175–87. [Accessed 4 October 2014].
  136. Hofmann SG, Sawyer AT, Korte KJ, Smits JA. Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy when Treating Anxiety Disorders? A Meta-Analytic Review. Int J Cogn Ther 2009;2(2):160–75. [Accessed 4 October 2014].
  137. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: Systematic review. Br J Psychiatry 2006;188:305–12. [Accessed 4 October 2014].
  138. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev 2007(1):CD004364. [Accessed 4 October 2014].
  139. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368(9553):2156–66. [Accessed 4 October 2014].
  140. Bystritsky A. Pharmacotherapy for generalized anxiety disorder [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  141. Berney P, Halperin D, Tango R, Daeniker-Dayer I, Schulz P. A major change of prescribing pattern in absence of adequate evidence: Benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacol Bull 2008;41(3):39–47. [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  142. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015 Apr 29; Epub 2015 Apr 29. [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  143. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. 2nd edn. Arlington VA: American Psychiatric Publishing, Inc; 2009. [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  144. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: A systematic review and meta-analysis. Psychother Psychosom 2013;82(6):355–62. [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  145. Moylan S, Staples J, Ward SA, et al. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol 2011;31(5):647–52. [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  146. Bostwick JR, Casher MI, Yasugi S. Benzodiazepines: A versatile clinical tool. Curr Psychiatr 2012;11(4). [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  147. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005;10(1):49–56. [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  148. Scottish Intercollegiate Guidelines Network. The Management of Harmful Drinking and Alcohol Dependence in Primary Care. Guideline No.74. Edinburgh: SIGN, Healthcare Improvement Scotland; 2004. [internet]. Waltham, MA: UpToDate; 2013. [Accessed April 2015].
  149. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. London: NICE; 2011. [Accessed April 2015].
  150. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010(3):CD005063. [Accessed April 2015].
  151. Gitlow S. Substance Use Disorders: A Practical Guide. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. [Accessed April 2015].
  152. Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2013;2:CD008502. [Accessed April 2015].
  153. Lingford-Hughes AR, Welch S, Peters L, Nutt DJ, British Association for Psychopharmacology ERG. BAP updated guidelines: Evidencebased guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP. J Psychopharmacol 2012;26(7):899–952. [Accessed April 2015].
  154. The Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004;38(5):280–305. [Accessed April 2015].
  155. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults: A national clinical guideline. Guideline No. 70. Edinburgh: SIGN, Healthcare Improvement Scotland; 2003. [Accessed April 2015].
  156. Walker C, Brown K, Peterson C, et al. A socio-economic longitudinal study of epilepsy: Needs, perceptions and experiences of people with epilepsy. Epilepsy Foundation of Victoria and Epilepsy Australia; 2011. [Accessed April 2015].
  157. Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009(3):CD005170. [Accessed April 2015].
  158. Witek MW, Rojas V, Alonso C, Minami H, Silva RR. Review of benzodiazepine use in children and adolescents. Psychiatr Q 2005;76(3):283–96. [Accessed April 2015].
  159. Harbord MG, Kyrkou NE, Kyrkou MR, Kay D, Coulthard KP. Use of intranasal midazolam to treat acute seizures in paediatric community settings. J Paediatr Child Health 2004;40(9-10):556–58. [Accessed April 2015].
  160. Humphries LK, Eiland LS. Treatment of acute seizures: is intranasal midazolam a viable option? J Pediatr Pharmacol Ther 2013;18(2):79–87. [Accessed April 2015].
  161. Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007;16(11):1203–10. [Accessed April 2015].
  162. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013;35(1):3–8. [Accessed April 2015].
  163. Maine Benzodiazepine Study Group. Guidelines for the use of benzodiazepines in office practice in the state of Maine. Maine: Maine Benzodiazepine Study Group; 2008. [Accessed April 2015].
  164. Uzun S, Kozumplik O, Jakovljevic M, Sedic B. Side effects of treatment with benzodiazepines. Psychiatr Danub 2010;22(1):90–93. [Accessed April 2015].
  165. Yoshida K, Smith B, Kumar R. Psychotropic drugs in mothers’ milk: A comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. J Psychopharmacol 1999;13(1):64–80. [Accessed April 2015].
  166. Pons G, Rey E, Matheson I. Excretion of psychoactive drugs into breast milk. Pharmacokinetic principles and recommendations. Clin Pharmacokinet 1994;27(4):270–89. [Accessed April 2015].
  167. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ 2005;331(7526):1169. [Accessed April 2015].
  168. Windle A, Elliot E, Duszynski K, Moore V. Benzodiazepine prescribing in elderly Australian general practice patients. Aust N Z J Public Health 2007;31(4):379–81. [Accessed April 2015].
  169. Takkouche B, Montes-Martinez A, Gill SS, Etminan M. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 2007;30(2):171–84. [Accessed April 2015].
  170. Council of the College of Psychiatry Ireland. A consensus statement on the use of benzodiazepines in specialist mental health services: EAP03/2012 Position Paper; 2012. [Accessed April 2015].
  171. Levy HB. Non-benzodiazepine hypnotics and older adults: what are we learning about zolpidem? Expert Rev Clin Pharmacol 2014;7(1):5–8. [Accessed April 2015].
  172. Bourgeois J, Elseviers MM, Van Bortel L, Petrovic M, Vander Stichele RH. Sleep quality of benzodiazepine users in nursing homes: A comparative study with nonusers. Sleep Med 2013;14(7):614–21. [Accessed April 2015].
  173. Iliffe S, Curran HV, Collins R, et al. Attitudes to long-term use of benzodiazepine hypnotics by older people in general practice: Findings from interviews with service users and providers. Aging Ment Health 2004;8(3):242–48. [Accessed April 2015].
  174. Gilbert A, Owen N, Innes JM, Sansom L. Trial of an intervention to reduce chronic benzodiazepine use among residents of aged-care accommodation. Aust N Z J Med 1993;23(4):343–47. [Accessed April 2015].
  175. Jones KA, Nielsen S, Bruno R, Frei M, Lubman DI. Benzodiazepines – their role in aggression and why GPs should prescribe with caution. Aust Fam Physician 2011;40(11):862–65. [Accessed April 2015].
  176. Briesacher BA, Soumerai SB, Field TS, Fouayzi H, Gurwitz JH. Medicare part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med 2010;170(8):693–98. [Accessed April 2015].
  177. NSW Department of Health. NSW Clinical Guidelines: For the care of persons with comorbid mental illness and substance use disorders in acute care settings. Sydney: NSW Department of Health; 2009. [Accessed April 2015].
  178. Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US healthcare system. Addiction 2010;105(10):1776–82. [Accessed April 2015].
  179. Brennan MJ, Lieberman JA 3rd. Sleep disturbances in patients with chronic pain: effectively managing opioid analgesia to improve outcomes. Curr Med Res Opin. 2009 May;25(5):1045-55. [Accessed April 2015].
  180. Mills K, Deady M, Proudfoot H, et al. Guidelines on the management of co-occuring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2010. [Accessed April 2015].
  181. Darke S, Ross J. The use of antidepressants among injecting drug users in Sydney, Australia. Addiction 2000;95(3):407–17. [Accessed April 2015].
  182. Darke S, Hall W, Ross M, Wodak A. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug Alcohol Depend 1992;31(1):31–36. [Accessed April 2015].
  183. Darke S, Ross J, Mills K, Teesson M, Williamson A, Havard A. Benzodiazepine use among heroin users: baseline use, current use and clinical outcome. Drug Alcohol Rev 2010;29(3):250–55. [Accessed April 2015].
  184. Austroads. Assessing fitness to drive for commercial and private vehicle drivers. 4th edn. Sydney: Austroads; 2013. [Accessed April 2015].
  185. Bond A, Lader M. Anxiolytics and sedatives. In: Verster JC, Brady K, Galanter M, Conrod P, editors. Drug abuse and addiction in medical illness: Causes, consequences and treatment. New York: Springer; 2012. [Accessed April 2015].
  186. Krystal AD. The treatment of primary insomnia. CNS Spectr 2009;14(12 Suppl 13):6–10. [Accessed April 2015].
  187. Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Benzodiazepines. J Pain Symptom Manage 2014;47(5):955–64. [Accessed April 2015].
  188. National Prescribing Service (NPS). NPS News: Which treatment for what anxiety disorder? Sydney: NPS; 2009. [Accessed April 2015].
  189. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009;23(1):19–34. [Accessed April 2015].
  190. Joint National Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2011. [Accessed April 2015].
  191. Parr JM, Kavanagh DJ, Cahill L, Mitchell G, Mc DYR. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 2009;104(1):13–24. [Accessed April 2015].
  192. Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: Cluster randomised controlled trial in primary care. Br J Psychiatry 2014;204(6):471–79. [Accessed April 2015].
  193. Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management i [Accessed April 2015].
This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log

Advertising